Kevin Van der Jeught
Kevin Van der Jeught
Geverifieerd e-mailadres voor iu.edu
TitelGeciteerd doorJaar
Targeting the tumor microenvironment to enhance antitumor immune responses
K Van der Jeught, L Bialkowski, L Daszkiewicz, K Broos, C Goyvaerts, ...
Oncotarget 6 (3), 1359, 2015
502015
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice
T Liechtenstein, N Perez-Janices, M Gato, F Caliendo, G Kochan, ...
Oncotarget 5 (17), 7843, 2014
412014
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
K Van der Jeught, PT Joe, L Bialkowski, C Heirman, L Daszkiewicz, ...
Oncotarget 5 (20), 10100, 2014
382014
Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells
S Van Lint, D Renmans, K Broos, L Goethals, S Maenhout, D Benteyn, ...
Cancer immunology research 4 (2), 146-156, 2016
372016
Drug resistance and new therapies in colorectal cancer
K Van der Jeught, HC Xu, YJ Li, XB Lu, G Ji
World journal of gastroenterology 24 (34), 3834, 2018
352018
Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon
K Broos, K Van der Jeught, J Puttemans, C Goyvaerts, C Heirman, ...
Molecular Therapy-Nucleic Acids 5, e326, 2016
312016
Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma
A Krasniqi, M D'Huyvetter, C Xavier, K Van der Jeught, S Muyldermans, ...
Molecular cancer therapeutics 16 (12), 2828-2839, 2017
162017
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours
L Bialkowski, A Van Weijnen, K Van der Jeught, D Renmans, ...
Scientific reports 6, 22509, 2016
162016
Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
Y Liu, J Xu, HH Choi, C Han, Y Fang, Y Li, K Van der Jeught, H Xu, ...
Nature communications 9 (1), 1-16, 2018
82018
Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety
K Van Der Jeught, S De Koker, L Bialkowski, C Heirman, P Tjok Joe, ...
ACS nano 12 (10), 9815-9829, 2018
82018
Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
Y Liu, H Xu, K Van der Jeught, Y Li, S Liu, L Zhang, Y Fang, X Zhang, ...
The Journal of clinical investigation 128 (7), 2951-2965, 2018
82018
Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20
A Krasniqi, M Bialkowska, C Xavier, K Van der Jeught, S Muyldermans, ...
New biotechnology 45, 69-79, 2018
72018
Immune checkpoint blockade combined with IL‐6 and TGF‐β inhibition improves the therapeutic outcome of m RNA‐based immunotherapy
L Bialkowski, K Van der Jeught, S Bevers, P Tjok Joe, D Renmans, ...
International journal of cancer 143 (3), 686-698, 2018
72018
Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy
K Van der Jeught, S Van Lint, K Thielemans, K Breckpot
Oncoimmunology 4 (5), e1005504, 2015
62015
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
J Xu, Y Liu, Y Li, H Wang, S Stewart, K Van der Jeught, P Agarwal, ...
Nature nanotechnology 14 (4), 388-397, 2019
32019
Adjuvant-enhanced mRNA vaccines
L Bialkowski, K Van der Jeught, D Renmans, A van Weijnen, C Heirman, ...
RNA Vaccines, 179-191, 2017
32017
Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
Y Li, Y Liu, H Xu, G Jiang, K Van der Jeught, Y Fang, Z Zhou, L Zhang, ...
Nature communications 9 (1), 1-15, 2018
22018
Author Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
J Xu, Y Liu, Y Li, H Wang, S Stewart, K Van der Jeught, P Agarwal, ...
Nature Nanotechnology, 1-1, 2020
2020
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–18